GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

NCT07086404 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Idiopathic Inflammatory Myopathy (IIM)

Interventions

DRUG: GC012F Injection infusion

Sponsor

Daishi Tian

Collaborators

AstraZeneca Global R&D (China) Co., Ltd.
Gracell Biotechnologies (Shanghai) Co., Ltd.